Reasons for acceptance and refusal of early palliative care in patients included in early-phase clinical trials in a regional comprehensive cancer centre in France: protocol for a qualitative study
Gisèle Chvetzoff(Université Claude Bernard Lyon 1), Véronique Christophe(Université Claude Bernard Lyon 1), Françoise Ducimetière(Centre Léon Bérard), Philippe A. Cassier(Lyon College), Bénédicte Mastroïanni(Centre Léon Bérard), Magali Girodet(Université Claude Bernard Lyon 1), Manon Britel(Centre Léon Bérard), Julie Duranti(Centre Léon Bérard), Armelle Vinceneux(Centre Léon Bérard), Valentine Baudry(Université Claude Bernard Lyon 1), Julien Gautier(Centre Léon Bérard), Johanna Despax(Centre Léon Bérard), Mehdi Brahmi(Centre Léon Bérard), Hélène Vanacker(Centre Léon Bérard), Olivier Renard(Centre Léon Bérard), Amélie Anota(Centre Léon Bérard)
Cited by 5
Related Papers
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
|Clinical Cancer Research|2012|233
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
|Cancer Research|2023|37
Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
|Cancers|2023|20